Nuvectis Pharma Inc Total Assets
Nuvectis Pharma Inc total assets. Based on the latest financial reports, Nuvectis Pharma Inc (NVCT) holds total assets worth $22.38 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Nuvectis Pharma Inc (NVCT) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Nuvectis Pharma Inc (2020–2025)
Total assets of Nuvectis Pharma Inc from 2020 to 2025. This chart illustrates how Nuvectis Pharma Inc's total assets have evolved over time, based on quarterly financial data. See latest Nuvectis Pharma Inc stock price today for real-time trading data and today's change.
Nuvectis Pharma Inc - Asset Composition Analysis
Nuvectis Pharma Inc Total Assets Breakdown (December 2025)
Nuvectis Pharma Inc total assets breakdown as of December 2025. Nuvectis Pharma Inc's total assets of $22.38 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 99.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Nuvectis Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Nuvectis Pharma Inc (NVCT) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nuvectis Pharma Inc's current assets represent 100.0% of total assets in 2025, an increase from 87.6% in 2020.
- Cash Position: Cash and equivalents constituted 99.8% of total assets in 2025, up from 86.3% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Nuvectis Pharma Inc Competitors by Total Assets
Key competitors of Nuvectis Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Nuvectis Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.68 | 2.66 | 13.76 |
| Quick Ratio | 1.68 | 2.66 | 13.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.08 Million | $16.87 Million | $6.31 Million |
Nuvectis Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Nuvectis Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 87.79 |
| Latest Market Cap to Assets Ratio | 19.91 |
| Asset Growth Rate (YoY) | 70.4% |
| Total Assets | $31.71 Million |
| Market Capitalization | $631.34 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Nuvectis Pharma Inc's assets at a significant premium (19.91x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Nuvectis Pharma Inc's assets grew by 70.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nuvectis Pharma Inc (2020–2025)
The table below shows the annual total assets of Nuvectis Pharma Inc from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $31.71 Million | +70.41% |
| 2024-12-31 | $18.61 Million | -3.01% |
| 2023-12-31 | $19.18 Million | -5.98% |
| 2022-12-31 | $20.41 Million | +206.52% |
| 2021-12-31 | $6.66 Million | 0.00% |
| 2020-12-31 | $6.66 Million | -- |
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was forme… Read more